Your shopping cart is currently empty

NVP-2 is an effective and selective ATP-competitive cyclin-dependent kinase 9 (CDK9) probe. NVP-2 induces cell apoptosis. NVP-2 inhibits CDK9/CycT activity (IC50: 0.514 nM). NVP-2 shows inhibitory effcts on CDK1/CycB, CDK2/CycA and CDK16/CycY kinases (IC50: 0.584 μM, 0.706 μM, and 0.605 μM, respectively).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $50 | In Stock | In Stock | |
| 2 mg | $72 | In Stock | In Stock | |
| 5 mg | $122 | In Stock | In Stock | |
| 10 mg | $213 | In Stock | In Stock | |
| 25 mg | $463 | In Stock | In Stock | |
| 50 mg | $683 | In Stock | In Stock | |
| 100 mg | $973 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $137 | In Stock | In Stock |
| Description | NVP-2 is an effective and selective ATP-competitive cyclin-dependent kinase 9 (CDK9) probe. NVP-2 induces cell apoptosis. NVP-2 inhibits CDK9/CycT activity (IC50: 0.514 nM). NVP-2 shows inhibitory effcts on CDK1/CycB, CDK2/CycA and CDK16/CycY kinases (IC50: 0.584 μM, 0.706 μM, and 0.605 μM, respectively). |
| Targets&IC50 | CDK9:0.5 nM (IC50) |
| In vitro | NVP-2 exhibits anti-proliferative activity against leukemia cells, specifically targeting KOPT-K1, Jurkat, P12-ICHIKAWA, DU.528, MOLT 16, HSB-2, PF-382, SKW-3, SUP-T11, DND-41, and HPB-ALL cells with IC50 values of 0.1688 μM, 0.1233 μM, 0.5736 μM, 0.1575 μM, 0.1620 μM, 0.1585 μM, 0.1808 μM, 0.2589 μM, 0.0918 μM, and 0.3023 μM, respectively. NVP-2 (0-10 nM; 72 hours) demonstrates CRBN-dependent anti-proliferative and pro-apoptotic effects in MOLT4 cells (IC50: 9 nM). At 250 nM for 24 hours, NVP-2 induces apoptosis in MOLT4 cells, increasing caspase-3 and γH2A.X expression, although this effect is significantly reduced upon compound washout. Additionally, NVP-2 (250 nM-1 μM; 6 hours) engages CDK9 in both wildtype and CRBN - / - MOLT4 cells without affecting CDK2 and CDK7. |
| Molecular Weight | 513.07 |
| Formula | C27H37ClN6O2 |
| Cas No. | 1263373-43-8 |
| Smiles | COC[C@@H](C)N[C@H]1CC[C@@H](CC1)Nc1cc(c(Cl)cn1)-c1cccc(NCC2(CCOCC2)C#N)n1 |
| Relative Density. | 1.23 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 250 mg/mL (487.26 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (7.8 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.